You are here

Herbert Smith Freehills advises Sanofi on €300 million equity investment in Innovent 史密夫斐尔律师事务所就赛诺菲对信达生物3亿欧元股权投资提供法律服务

19 August 2022 | China
News

Share

Leading international law firm Herbert Smith Freehills has advised innovative global healthcare company Sanofi on its €300 million strategic equity investment in Chinese biopharmaceutical company Innovent Biologics.

The transaction sees Sanofi invest €300 million in Innovent through subscription of new common shares at HK $42.42 per share. Subject to mutual agreement, Sanofi will have the right to acquire additional Innovent new common shares for €300 million.

Sanofi has also formed a strategic collaboration with Innovent to accelerate the development of Sanofi's oncology medicines and expand its presence in China.

The Herbert Smith Freehills team was led by Hong Kong partner Jeremy Shen, assisted by senior associate Jaime Fong and associate Samuel Au. "We are delighted to have advised Sanofi on this tremendous investment in a Chinese biopharmaceutical company," said Jeremy. "We congratulate Sanofi on its second successful equity investment in the Chinese healthcare sector in recent months."  

In July, Herbert Smith Freehills and its joint operation partner Kewei in Shanghai advised Sanofi on its participation in the initial public offering and Hong Kong listing of Chinese technology solutions services provider ClouDr as a cornerstone investor. Kewei international partner Gavin Guo led the Kewei team on both transactions.

"Herbert Smith Freehills and Kewei are clear market leaders in China, and we are pleased to leverage our strength to help our longstanding client to achieve its strategic objectives," said Hubert Segain, Head of Corporate in Paris.

史密夫斐尔律师事务所为创新的全球医疗健康公司赛诺菲对中国生物制药公司信达生物(Innovent Biologics)进行3亿欧元战略股权投资提供咨询。

在该笔交易中,赛诺菲将以每股42.42港元的价格以新股认购方式购入价值3亿欧元的信达生物普通股份。若双方另行协议,赛诺菲有权额外购入价值3亿欧元的信达生物普通股份。

赛诺菲还与信达生物达成战略合作,以加快赛诺菲肿瘤药物的开发,并开展在中国的推广。

史密夫斐尔香港办公室合伙人沈志良(Jeremy Shen)率领律师团队为赛诺菲提供咨询,方靖颐(Senior Associate)和区健聪(Associate)提供协助。沈志良表示:“我们很荣幸能够在赛诺菲向中国生物制药公司进行的这笔巨额投资中提供法律建议。衷心祝贺赛诺菲成功完成了近几个月来在中国医疗健康行业的第二笔股权投资。”

今年七月,史密夫斐尔与科伟律师事务所的联营办公室为赛诺菲作为基石投资者参与智云健康在香港首次公开募股和上市提供咨询。在两笔交易中,科伟国际资深顾问郭武汉律师(Gavin Guo)均率领科伟团队为客户提供服务。

史密夫斐尔巴黎公司事务主管合伙人Hubert Segain表示: “史密夫斐尔和科伟都是中国市场的领先律所,我们很高兴能够凭借优势,助力我们的长期客户实现其战略目标。”

 

See how we help our clients in

Capital Markets

Learn More

主要联系人

Media Contact

For further information on this news article, please contact:

Sally Greig, Head of Communications, Asia

Hong Kong
Tel: 
+852 21014624

VIVIAN HUANG, COMMUNICATIONS MANAGER, CHINA

Beijing
Tel: 
+86 10 65355025